Results 191 to 200 of about 14,520 (202)

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

European Journal of Cancer, 2018
Mario Campone, Seock-Ah Im, Mark Clemons   +2 more
exaly  

Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials

British Journal of Cancer, 2004
Ignace Vergote, J F R Robertson, Vergote I   +2 more
exaly  

Fulvestrant

Reactions Weekly, 2018
openaire   +1 more source

Fulvestrant/palbociclib

Reactions Weekly, 2019
  +4 more sources

Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer

Journal of Steroid Biochemistry and Molecular Biology, 2017
Kouki Tsuboi, Toru Hanamura, Tatsuyuki Gohno   +2 more
exaly  

Fulvestrant/palbociclib

Reactions Weekly, 2022
openaire   +1 more source

Fulvestrant/palbociclib

Reactions Weekly, 2023
openaire   +1 more source

Fulvestrant/palbociclib

Reactions Weekly, 2017
openaire   +2 more sources

Fulvestrant/palbociclib

Reactions Weekly
  +4 more sources

Fulvestrant

2007
openaire   +1 more source